Oxford BioMedica (GB:OXB) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oxford Biomedica has appointed Colin Bond as a Non-Executive Director, effective January 2025, as part of its board succession planning. Bond brings extensive experience in the biopharma and CDMO sectors, having played key roles in companies like Sandoz and Vifor Pharma. This strategic move is aimed at bolstering Oxford Biomedica’s growth and innovation in the cell and gene therapy industry.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
